Skip to content

Yoga Therapy and Aerobic Exercise on Anti-Mullerian Hormone in Young Women With Polycystic Ovary Syndrome

Yoga Therapy and Aerobic Exercise on Anti-Mullerian Hormone and Other Biochemical Markers in Young Women With Polycystic Ovary Syndrome

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04335227
Enrollment
128
Registered
2020-04-06
Start date
2021-11-14
Completion date
2023-04-14
Last updated
2021-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-Mullerian Hormone Deficiency, Female Infertility Endocrine, Polycystic Ovary Syndrome

Keywords

Yoga therapy, Aerobic exercise training, Aerobic exercise, Aerobic training, Polycystic ovary syndrome, Antimullerian hormone

Brief summary

Weight loss and lifestyle modifications are much required in women with Polycystic ovarian syndrome (PCOS). Yoga has gained great importance as an alternate medicine in recent years which is helpful in lifestyle modifications. Weight loss can be achieved by regular aerobic activity. In recent years, excessive production of anti-mullerian hormone (AMH) has been considered as the etiology of PCOS. AMH is also emerging as a diagnostic and screening tool for PCOS. Effect of yoga therapy on adolescent girls have proved to be effective. But, researches on young women undergoing yoga therapy and combined effect of aerobic exercise and yoga therapy are still lacking. Hence, the investigators aimed t o establish the benefits of yoga therapy and aerobic exercise on Anti-Mullerian Hormone and other biochemical markers in young women with polycystic ovary syndrome.

Detailed description

A total of 128 female with PCOS will be recruited by the simple random sampling (random number generator) to participate in randomized, single blind randomized controlled, study. Recruited patients with 128 female with PCOS will be randomly divided into four groups, yoga therapy (YT) group, aerobic exercise (AE) group, combined YT and AE (cYTAE) group and control group. Duration of the intervention will be 60 minutes in one session for 6 days/week for 12 weeks. Thus, each women with PCOS will receive 72 sessions in total, except in control group. Anti-Müllerian hormone (AMH) and other biochemical markers such as, Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), Testosterone, Prolactin, Thyroid-stimulating hormone (TSH) Ultrasensitive, Dehydroepiandrosterone sulfate (DHEAS), insulin fasting, glucose fasting, HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) and the lipid profiles which includes, total cholesterol, High-density lipoprotein cholesterol (HDL-C), Low-density lipoprotein cholesterol (LDL-C) and serum triglycerides. In addition to the above biochemical markers, transvaginal ultrasound to estimate antral follicle count (AFC) will be recorded at baseline and at the end of 12-week post-intervention period. Following the 12-week intervention, follow-up of another 12-week will be carried out to determine the retention of treatment effects.

Interventions

OTHERStructured yoga therapy program

Structured yoga therapy prepared according to traditional yoga scriptures of Patanjali yoga sutras will be administered to 32 females with PCOS. The structured yoga therapy which includes, Surya Namaskara (Sun Salutation) and asanas performed in four positions, standing, sitting, supine and prone for total duration of 60 minutes. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian

OTHERAerobic exercise training program

Thirty two females with PCOS in aerobic exercise (AE) group will be subjected to aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks, in the light of guidelines framed by American College of Sports Medicine (ACSM). Aerobic exercise volume for each female recruited will be set at greater than 500 and up to 1000 MET-min/week, which will be approximately equal to 1000 kcal/week. They will be made sure that they exercise for minimum duration of 150 min/week and thereby covering 5400 to 7900 steps/day in pedometer readings. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian

OTHERCombined yoga and aerobic training program

Thirty two females with PCOS in combined yoga therapy and aerobic exercise (cYTAE) group will be subjected to three days of structured yoga therapy and three days of aerobic training of vigorous intensity. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian

Thirty two females with PCOS will be asked to undergo only nutritional management uniquely prepared by dietitian

Sponsors

Maharishi Markendeswar University (Deemed to be University)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Lab technician who test the blood samples of the female with Polycystic Ovary Syndrome (PCOS) will be blinded to the trial

Intervention model description

Recruited female with PCOS with 128 female with PCOS will be randomly divided into four parallel groups, yoga therapy (YT) group, aerobic exercise (AE) group, combined YT and AE (cYTAE) group and control group

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

* Female in age between 18 and 30 years * Female with at least two-thirds of the features listed in the Rotterdam criteria for PCOS were included in the study * Oligomenorrhea or amenorrhea (an absence of menstruation for 45 or more days and/or fewer than 9 menses per year) * Hyperandrogenism (a score of 8 or higher ( ≥ 8) on the modified Ferriman-Gallwey scale) * Polycystic ovaries (presence of more than 12 cysts \< 9 mm in diameter in single ovary, usually combined with an ovarian volume \> 10 ml

Exclusion criteria

* On regular hormonal treatment * Oral contraceptives * Insulin-sensitizing agents in the previous 6 weeks * Smoking in less than 48 hours * Alcohol in less than 48 hours * History of thyroid abnormalities * Practicing regular yoga asanas and pranayama * Regular aerobic training program

Design outcomes

Primary

MeasureTime frameDescription
Serum Anti-Mullerian hormone ConcentrationChange from Baseline Serum Anti-Mullerian hormone Concentration at 12 weeksSerum Anti-Mullerian hormone will be determined by blinded lab technician

Secondary

MeasureTime frameDescription
Serum Follicle-stimulating hormone ConcentrationChange from Baseline Serum Follicle-stimulating hormone Concentration at 12 weeksSerum Follicle-stimulating hormone will be determined by blinded lab technician
Serum Luteinizing hormone ConcentrationChange from Baseline Serum Luteinizing hormone Concentration at 12 weeksSerum Luteinizing hormone will be determined by blinded lab technician
Serum Testosterone ConcentrationChange from Baseline Serum Testosterone Concentration at 12 weeksSerum Testosterone will be determined by blinded lab technician
Serum Prolactin ConcentrationChange from Baseline Serum Prolactin Concentration at 12 weeksSerum Prolactin will be determined by blinded lab technician
Serum Thyroid-stimulating hormone ConcentrationChange from Baseline Serum Thyroid-stimulating hormone Concentration at 12 weeksSerum Thyroid-stimulating hormone will be determined by blinded lab technician
Antral follicle countChange from Baseline Antral follicle count at 12 weeksAntral follicle count will be determined by blinded gynaecologist
Serum Insulin fasting ConcentrationChange from Baseline Serum Insulin fasting Concentration at 12 weeksSerum Insulin fasting will be determined by blinded lab technician
Serum Glucose fasting ConcentrationChange from Baseline Serum Glucose fasting Concentration at 12 weeksSerum Glucose fasting will be determined by blinded lab technician
Homeostatic Model Assessment for Insulin ResistanceChange from Baseline Homeostatic Model Assessment for Insulin Resistance at 12 weeksHomeostatic Model Assessment for Insulin Resistance will be determined by blinded lab technician
Concentration of Lipid profiles in serumChange from Baseline Concentration of Lipid profiles in serum at 12 weeksSerum total cholesterol, Serum High-density lipoprotein cholesterol, Serum Low-density lipoprotein cholesterol and serum triglycerides
Serum Dehydroepiandrosterone sulfate ConcentrationChange from Baseline Serum Dehydroepiandrosterone sulfate Concentration at 12 weeksSerum Dehydroepiandrosterone sulfate will be determined by blinded lab technician

Countries

India

Contacts

Primary ContactAsir J Samuel, MPT, PhD
asirjohnsamuel@mmumullana.org+918059930222

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026